Optomed Q4: Initial take – Sales in line and slightly higher costs than expected - Redeye

Redeye provides an initial take following the release of Optomed’s Q4 2024 report. Sales aligned with our expectations, and costs were a bit higher than projected. Overall, we note that the company has a positive outlook for 2025, which will be an important year for the company. We will provide an update, digging deeper into the report.

Länk till analysen i sin helhet: https://www.redeye.se/research/1075779/optomed-q4-initial-take-sales-in-line-and-slightly-higher-costs-than-expected?utm_source=finwire&utm_medium=RSS